Program
RSV vaccine formulation 1 dose
Also written as “RSV vaccine formulation 2 dose”, “RSV vaccine formulation 3 dose” and “RSV vaccine formulation 4 dose”.
Its studies are mostly in Respiratory Syncytial Virus Infections, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 20 open or running | phase 2since Jul 27, 2020 | Jul 27, 2020 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 27, 2020First study: phase 2 study in Respiratory Syncytial Virus InfectionsFirst studyNCT04491877 · 259 enrolled · United States, Chile, Honduras
- Jul 8, 2025Phase 1 study in Respiratory Syncytial Virus InfectionsNCT07071558 · 240 enrolled · Australia
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“RSV vaccine formulation 1 dose”name, by rule
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07071558Respiratory Syncytial Virus Infections · Australia | 1 | Completed | Mar 17, 2026 | 240 |
| NCT04491877Respiratory Syncytial Virus Infections · United States, Chile, Honduras | 2 | Completed | Apr 13, 2023 | 259 |
How it is read
Names in the registry
- “RSV vaccine formulation 1 dose”, 1 entry
- “RSV vaccine formulation 2 dose”, 1 entry
- “RSV vaccine formulation 3 dose”, 1 entry
- “RSV vaccine formulation 4 dose”, 1 entry
- “RSV vaccine formulation 5 dose”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.